Iain B McInnes (Iain McInnes, I B McInnes)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 51

Top Venues

RMD open

Clinical rheumatology

Rheumatology and therapy

JMIR research protocols

University of Glasgow (BSC)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Glasgow

United Kingdom

BSC

University of Glasgow

United Kingdom

PHD

Publications

Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Meredith Leston, Jose M Ordóñez-Mena, Mark P Joy, Simon de Lusignan, Frederick David Richard Hobbs, Iain B McInnes, Lennard Y W Lee
Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study. JMIR research protocols 13 (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy 11 (1) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Meredith Leston, Jose M Ordóñez-Mena, Mark P Joy, Simon de Lusignan, Frederick David Richard Hobbs, Iain B McInnes, Lennard Y W Lee
Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study. JMIR research protocols 13 (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy 11 (2) (2024)
Phillip J Mease, Joseph Frank Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewe, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C Coates
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatology and therapy (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy 11 (1) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Meredith Leston, Jose M Ordóñez-Mena, Mark P Joy, Simon de Lusignan, Frederick David Richard Hobbs, Iain B McInnes, Lennard Y W Lee
Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study. JMIR research protocols 13 (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Meredith Leston, Jose M Ordóñez-Mena, Mark P Joy, Simon de Lusignan, Frederick David Richard Hobbs, Iain B McInnes, Lennard Y W Lee
Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study. JMIR research protocols 13 (2024)
Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P Kollmeier, Natalie J Shiff, Chenglong Han, May Shawi, William Tillett, Phillip J Mease
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. Rheumatology and therapy (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy (2024)
Dennis McGonagle, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, Phillip J Mease
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR open rheumatology (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Phillip J Mease, Alice B Gottlieb, Philip S Helliwell, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Kishimoto Mitsumasa, Proton Rahman
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical rheumatology (2023)
Mukanthu H Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, Derek S Gilchrist, Duncan Porter, Stefan Siebert, Carl S Goodyear, Iain B McInnes
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD open 9 (1) (2023)
Ciara M O'Brien, George D Kitas, Fiona Rayner, John Dudley Isaacs, Kenneth F Baker, Arthur G Pratt, Christopher Dominic Buckley, Karim Raza, Andrew Filer, Stefan Siebert, Iain B McInnes, Andrew McGucken, Sally A M Fenton, null null
Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study. Rheumatology international (2023)
Christina Charles-Schoeman, Ernest H S Choy, Iain B McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R Curtis
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD open 9 (4) (2023)
Mukanthu H Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, Derek S Gilchrist, Duncan Porter, Stefan Siebert, Carl S Goodyear, Iain B McInnes
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD open 9 (1) (2023)
Duncan Porter, Sahil Jain, Evelyn Qian, Fraser R Morton, Iain B McInnes
Time-varying risks of infection in patients as they proceed through the phases of 'pre-RA': results from the Scottish Early RA inception cohort. RMD open 9 (4) (2023)
Mukanthu H Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, Derek S Gilchrist, Duncan Porter, Stefan Siebert, Carl S Goodyear, Iain B McInnes
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD open 9 (1) (2023)
Kastriot Kastrati, Daniel Aletaha, Gerd-Rüdiger R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke J H Voshaar, Kevin L Winthrop, Josef S Smolen, Andreas Kerschbaumer
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD open 8 (2) (2022)
Carmel Stober, Iain B McInnes, Soumya Raychaudhuri, Phillip J Mease, Stephen R Pennington, Jose U Scher, Vinod Chandran, April W Armstrong, Maarten P T de Wit, Alberto Cauli, Deepak R Jadon, Thorvardur Jon Love, Philip S Helliwell, Denis O'Sullivan, Leonieke J J van Mens, Christopher T Ritchlin, Oliver M FitzGerald
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting. The Journal of rheumatology 49 (6 Suppl 1) (2022)
Katja Reuter, Carina Haupt, Anna Moltó, Andrew Cope, Ronald F Van Vollenhoven, Dirk Elewaut, Rik Lories, Iain B McInnes
Levelling the playing field of RMD research across Europe to address patients' needs: the emerging EULAR Research Centre. RMD open 8 (2) (2022)
Iain B McInnes, Laura Marie Sawyer, Kristen Markus, Corinne LeReun, Celia Sabry-Grant, Philip S Helliwell
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD open 8 (1) (2022)
Laura C Coates, Iain B McInnes, Joseph F Merola, Richard B Warren, Arthur Kavanaugh, Alice B Gottlieb, Laure Gossec, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Barbara Ink, Christopher T Ritchlin
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Iain B McInnes, Andrew J K Ostor, Phillip J Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, Atul Deodhar
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD open 8 (1) (2022)
Pavel V Ovseiko, Laure Gossec, Laura Andreoli, Uta Kiltz, Leonieke van Mens, Neelam Hassan, Marike van der Leeden, Heidi J Siddle, Alessia Alunno, Iain B McInnes, Nemanja S Damjanov, Florence Apparailly, Caroline Ospelt, Irene E van der Horst-Bruinsma, Elena Nikiphorou, Katie L Druce, Zoltán Szekanecz, Alexandre Sepriano, Tadej Avcin, George Bertsias, Georg Schett, Anne-Maree Keenan, Linda H Pololi, Laura C Coates
Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force. RMD open 8 (2) (2022)
Keith Colaco, Ker-Ai Lee, Shadi Akhtari, Raz Winer, Paul I Welsh, Naveed Sattar, Iain B McInnes, Vinod Chandran, Paula Harvey, Richard J Cook, Dafna D Gladman, Vincent Piguet, Lihi Eder
Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis & rheumatology (Hoboken, N.J.) 74 (7) (2022)
Iain B McInnes, Zoltán Szekanecz, Dennis McGonagle, Walter P Maksymowych, Alexander Pfeil, Ralph Lippe, In-Ho Song, Apinya Lertratanakul, Thierry Sornasse, Ana Biljan, Atul Deodhar
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford, England) (2021)
Stefan Siebert, Kristen Sweet, Bidisha Dasgupta, Kim Campbell, Iain B McInnes, Matthew J Loza
Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials. Arthritis & rheumatology (Hoboken, N.J.) 71 (10) (2019)
K A Bain, E McDonald, F Moffat, M Tutino, Madhura Castelino, Richard B Warren, J Cavanagh, Umer Zeeshan Ijaz, Stefan Siebert, Iain B McInnes, A Astrand, S Holmes, Simon W F Milling
Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. The British journal of dermatology 182 (1) (2019)

Iain B McInnes.css-eqlu8i{font-size:small;padding-left:4px;} (Iain McInnes, I B McInnes)

Publication Activity (10 Years)

Top Topics

Top Venues

Iain B McInnes (Iain McInnes, I B McInnes)